Sanofi (SAN) 주식 개요
헬스케어 회사인 Sanofi는 미국, 유럽 및 전 세계에서 치료 솔루션의 연구, 개발, 제조 및 마케팅에 종사하고 있습니다. 자세히 보기
SAN Community Fair Values
Create NarrativeSee what 219 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sanofi 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | €75.54 |
| 52주 최고가 | €91.15 |
| 52주 최저가 | €71.73 |
| 베타 | 0.28 |
| 1개월 변동 | 2.14% |
| 3개월 변동 | -1.76% |
| 1년 변동 | -12.04% |
| 3년 변동 | -20.06% |
| 5년 변동 | -14.37% |
| IPO 이후 변동 | 81.59% |
최근 뉴스 및 업데이트
Recent updates
내러티브 업데이트 • Jun 04
SAN: Future Upside Will Depend On AI Execution And R&D Pipeline Delivery
Analysts have nudged their fair value estimate for Sanofi higher from €95.53 to €97.10, citing slightly adjusted assumptions on discount rate, revenue growth, profit margins and future P/E as the basis for the updated price target. Analyst Commentary Bullish analysts framing the updated fair value for Sanofi around €97.10 are effectively signaling confidence that the company can execute in line with, or slightly ahead of, their refined assumptions on discount rate, revenue trajectory, margins and implied future P/E.분석 기사 • May 04
Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings
Shareholders appeared unconcerned with Sanofi's ( EPA:SAN ) lackluster earnings report last week. We think that the...내러티브 업데이트 • Apr 22
SAN: Future Upside Will Rely On Pipeline Delivery And Margin Execution
Sanofi's analyst price target has been adjusted slightly lower to €95.53 from €96.10, as analysts factor in marginally higher revenue growth expectations, a modestly lower profit margin and a revised forward P/E assumption. Analyst Commentary Recent Street research on large European financials and cross border bank transactions offers a useful lens for thinking about how analysts might be framing Sanofi's current valuation reset and execution risks, even though the specific notes focus on banks rather than pharmaceuticals.
새로운 내러티브 • Apr 14
Pipeline And Vaccine Catalysts Will Reshape This Pharma Leader Over The Next Decade
Catalysts About Sanofi Sanofi is a global biopharma group focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Apr 07
SAN: Future Upside Will Rely On Pipeline Delivery And Margin Expansion
Analysts trimmed Sanofi's fair value estimate by €2.00 to €96.10, citing updated assumptions that include slightly different revenue growth, a higher profit margin profile, and a lower future P/E multiple. Analyst Commentary Recent Street research on European financials and cross border bank deals offers some reference points that investors can use when thinking about Sanofi's updated fair value and how sentiment can swing as assumptions change.
새로운 내러티브 • Mar 31
Rising R&D Burden And Pipeline Risk Will Challenge Long Term Profitability
Catalysts About Sanofi Sanofi is a global biopharmaceutical company focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Mar 24
SAN: Future Upside Will Rely On Pipeline Execution And Margin Strength
Sanofi's analyst price target has been adjusted to €98.10 from €98.49 as analysts factor in slightly higher assumed revenue growth, stronger profit margins and a lower future P/E multiple in their updated models. Analyst Commentary Analysts updating their models for Sanofi are weighing the slightly higher revenue assumptions and stronger margin profile against a more conservative future P/E multiple.내러티브 업데이트 • Mar 09
SAN: Future Upside Will Rely On Pipeline Execution And Margin Resilience
Analysts have nudged their price target on Sanofi higher to €98.49, reflecting slightly firmer revenue growth assumptions and a nearly unchanged long-term profit margin and P/E outlook. Analyst Commentary Analysts covering Sanofi are broadly focused on how the updated €98.49 price target lines up with the company’s ability to execute on its plan, sustain its profit profile and justify its current P/E.내러티브 업데이트 • Feb 23
SAN: Future Upside Will Rely On Pipeline Delivery And Margin Stability
Analysts have trimmed their Sanofi price target slightly to €98.49. The change is tied to more cautious assumptions for revenue growth, profit margins and a modestly higher future P/E multiple.내러티브 업데이트 • Feb 09
SAN: Future Upside Will Depend On Pipeline Execution And Margin Resilience
Analysts have trimmed their Sanofi price targets slightly, with fair value moving from about €101 to about €99 as they factor in a modestly higher discount rate, slightly softer revenue growth assumptions around 3.6% and a marginally lower expected profit margin near 19.7%, paired with a future P/E closer to 12.8x. Analyst Commentary Recent updates to Sanofi valuation assumptions, including a modestly higher discount rate and slightly softer revenue and margin expectations, have led analysts to fine tune their views rather than overhaul them.내러티브 업데이트 • Jan 25
SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline
Analysts have trimmed their price target on Sanofi to reflect a fair value move from €102.77 to €100.96, citing updated assumptions around revenue growth, profit margins and future P/E levels. Analyst Commentary While the latest fair value trim for Sanofi is modest, it still reflects a tight range of outcomes that analysts see as reasonable based on current assumptions around growth, profitability and P/E levels.내러티브 업데이트 • Jan 11
SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline
Analysts have trimmed their fair value estimate for Sanofi from about €104.87 to roughly €102.77, pointing to slightly softer assumptions for revenue growth, profit margins and future P/E as key drivers of the updated price target outlook. Analyst Commentary Recent fair value adjustments for Sanofi sit against a backdrop of active price target revisions across European equities, including large financials, where several research desks have been updating their expectations.내러티브 업데이트 • Dec 25
SAN: Future Upside Will Depend On Pipeline Delivery And Cost Discipline
Analysts have trimmed their price target for Sanofi modestly, cutting their fair value estimate by about EUR 0.33 to roughly EUR 104.87. They cite slightly slower revenue growth, a softer profit margin profile, and a marginally higher future earnings multiple as the main factors behind this adjustment.내러티브 업데이트 • Dec 11
SAN: Future Returns Will Depend On Execution Of Late-Stage Pipeline
Analysts have nudged their fair value estimate for Sanofi slightly lower from EUR 106.26 to about EUR 105.20, citing marginally softer revenue growth assumptions, partially offset by a modestly stronger profit margin outlook and a slightly reduced forward P E multiple. Analyst Commentary Analyst sentiment on Sanofi remains broadly constructive, with recent fair value adjustments reflecting a more nuanced balance between growth ambitions and execution risks.내러티브 업데이트 • Nov 27
SAN: Future Momentum Will Depend On Execution Of New Pipeline Approvals
Sanofi's analyst price target has been modestly adjusted downward from $106.85 to $106.26. Analysts point to slight improvements in profit margin and future valuation metrics while maintaining a broadly stable outlook.내러티브 업데이트 • Nov 10
SAN: Forward Momentum Will Rely On Pipeline Success And Operational Execution
Sanofi's analyst price target saw a slight decrease to $106.85 from $106.90. Analysts cite moderating revenue growth expectations and a slightly higher discount rate impacting the updated valuation.분석 기사 • Oct 31
We Think Sanofi's (EPA:SAN) Healthy Earnings Might Be Conservative
Sanofi's ( EPA:SAN ) recent earnings report didn't offer any surprises, with the shares unchanged over the last week...내러티브 업데이트 • Oct 27
Future Shareholder Returns Will Depend On Commercial Execution And Pipeline Momentum
Sanofi's analyst price target has been slightly lowered from €108.31 to €106.90. Analysts cite modest improvements in revenue growth and profit margin, but note a more conservative outlook for the company's future valuation.내러티브 업데이트 • Sep 12
Pipeline Advances And Acquisitions Will Expand Therapeutic Horizons
Sanofi's slight decline in future P/E alongside an improved net profit margin suggests a modestly stronger earnings outlook, although this was not enough to materially shift the consensus analyst price target, which decreased fractionally from €109.22 to €108.31. What's in the News FDA approved Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) after insufficient response to previous treatment, based on positive Phase 3 results; also approved in UAE and under review in EU and China, with Fast Track and Orphan Drug designations for multiple indications.분석 기사 • Jul 27
Cautious Investors Not Rewarding Sanofi's (EPA:SAN) Performance Completely
With a median price-to-earnings (or "P/E") ratio of close to 16x in France, you could be forgiven for feeling...주주 수익률
| SAN | FR Pharmaceuticals | FR 시장 | |
|---|---|---|---|
| 7D | -1.5% | -0.1% | 1.8% |
| 1Y | -12.0% | -5.6% | 4.6% |
수익률 대 산업: SAN은 지난 1년 동안 -5.6%의 수익을 기록한 French Pharmaceuticals 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: SAN은 지난 1년 동안 4.6%를 기록한 French 시장보다 저조한 성과를 냈습니다.
주가 변동성
| SAN volatility | |
|---|---|
| SAN Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in FR Market | 10.9% |
| 10% least volatile stocks in FR Market | 2.7% |
안정적인 주가: SAN는 지난 3개월 동안 French 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: SAN의 주간 변동성(3%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1994 | 74,846 | Belen Garijo Lopez | www.sanofi.com |
헬스케어 회사인 Sanofi는 미국, 유럽 및 전 세계에서 치료 솔루션의 연구, 개발, 제조 및 마케팅에 종사하고 있습니다. 면역학 및 염증, 희귀 질환, 신경학, 종양학, 기타 의약품 및 백신을 제공합니다. 또한 소아마비, 백일해, b형 헤모필루스 인플루엔자(Hib) 소아 백신, 디프테리아, 파상풍, 백일해, 소아마비, Hib, B형 간염을 예방하는 호흡기 세포융합 바이러스 예방 및 6가 혼합 백신, A형 간염, 장티푸스, 황열, 광견병 백신을 포함한 여행 및 풍토병 백신을 공급하고 있습니다.
Sanofi 기초 지표 요약
| SAN 기초 통계 | |
|---|---|
| 시가총액 | €91.92b |
| 순이익 (TTM) | €4.83b |
| 매출 (TTM) | €47.35b |
18.8x
주가수익비율(P/E)1.9x
주가매출비율(P/S)SAN는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| SAN 손익계산서 (TTM) | |
|---|---|
| 매출 | €47.35b |
| 매출원가 | €13.09b |
| 총이익 | €34.26b |
| 기타 비용 | €29.44b |
| 순이익 | €4.83b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Jul 30, 2026
| 주당순이익(EPS) | 4.02 |
| 총이익률 | 72.36% |
| 순이익률 | 10.20% |
| 부채/자본 비율 | 24.9% |
SAN의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
5.5%
현재 배당 수익률102%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/15 18:36 |
| 종가 | 2026/06/15 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Sanofi는 50명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |
| null null | Banco de Sabadell. S.A. |